← Leaderboards
Michael R Green
Univ Of Massachusetts Med Sch Worcester
$18,218,266
Attributed
$19,388,612
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–21$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$19,388,612 · 9
By mechanism
R01$19,388,612 · 9
Top collaborators
- Narendra Wajapeyee4 shared
Most similar at Univ Of Massachusetts Med Sch Worcester
Same institution · by research overlap
- Anthony N Imbalzano$13,747,391
- Shaoguang Li$10,655,005
- Charles G Sagerstrom$13,147,065
- Craig L Peterson$21,838,477
- William Edward Theurkauf$12,443,498
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseCellsGenetic TranscriptionProteinsGenesMediatingPathway InteractionsLaboratoriesSmall Hairpin RnaEpigenetic ProcessSplice SiteResearch StudyRna SplicingPlayProtein Structure FunctionGene Expression RegulationMolecularTranscription FactorExperimental StudyVirus ProteinIntermolecular InteractionTissue /Cell CultureGenome-WideInhibitor/Antagonist
Grant awards (62)
A Novel Druggable Epigenetic Vulnerability Pathway in HCC$585,065
R01 · FY2021 · CA · contact PI
Reactivation of Epigenetically Silenced FMR1 as a Therapeutic Approach for Fragile X Syndrome$418,750
R01 · FY2021 · MH · contact PI
Transcriptional Upregulation of the Epigenetically Repressed FXN Gene as a Therapeutic Approach for Friedreich Ataxia$366,406
R01 · FY2021 · NS · contact PI
Alternative Splicing and mRNA 3' End Formation in Normal Gene Regulation and Cancer Development$326,625
R01 · FY2021 · GM · contact PI
A Novel Druggable Epigenetic Vulnerability Pathway in HCC$590,486
R01 · FY2020 · CA · contact PI
Reactivation of Epigenetically Silenced FMR1 as a Therapeutic Approach for Fragile X Syndrome$418,750
R01 · FY2020 · MH · contact PI
Transcriptional Upregulation of the Epigenetically Repressed FXN Gene as a Therapeutic Approach for Friedreich Ataxia$366,406
R01 · FY2020 · NS · contact PI
Alternative Splicing and mRNA 3' End Formation in Normal Gene Regulation and Cancer Development$326,625
R01 · FY2020 · GM · contact PI
A Novel Druggable Epigenetic Vulnerability Pathway in HCC$565,390
R01 · FY2019 · CA · contact PI
Reactivation of Epigenetically Silenced FMR1 as a Therapeutic Approach for Fragile X Syndrome$418,750
R01 · FY2019 · MH · contact PI
Transcriptional Upregulation of the Epigenetically Repressed FXN Gene as a Therapeutic Approach for Friedreich Ataxia$366,406
R01 · FY2019 · NS · contact PI
Alternative Splicing and mRNA 3' End Formation in Normal Gene Regulation and Cancer Development$326,625
R01 · FY2019 · GM · contact PI
A Novel Druggable Epigenetic Vulnerability Pathway in HCC$599,752
R01 · FY2018 · CA · contact PI
Reactivation of Epigenetically Silenced FMR1 as a Therapeutic Approach for Fragile X Syndrome$418,750
R01 · FY2018 · MH · contact PI
Alternative Splicing and mRNA 3' End Formation in Normal Gene Regulation and Cancer Development$326,625
R01 · FY2018 · GM · contact PI
Reactivation of Epigenetically Silenced FMR1 as a Therapeutic Approach for Fragile X Syndrome$418,750
R01 · FY2017 · MH · contact PI
Identification and Characterization of Genes that Suppress BCR-ABL+ Leukemia$347,563
R01 · FY2017 · CA · contact PI
Identification and Characterization of Genes that Suppress BCR-ABL+ Leukemia$347,563
R01 · FY2016 · CA · contact PI
Identification and Characterization of Genes that Suppress BCR-ABL+ Leukemia$347,563
R01 · FY2015 · CA · contact PI
Identification and Characterization of Genes that Suppress BCR-ABL+ Leukemia$337,136
R01 · FY2014 · CA · contact PI
Identification and Characterization of Genes that Suppress BCR-ABL+ Leukemia$345,488
R01 · FY2013 · CA · contact PI
Splicing of mRNA Precursors$314,310
R01 · FY2013 · GM · contact PI
Mechanisms of Eukaryotic Transcriptional Regulation$298,596
R01 · FY2013 · GM · contact PI
Splicing of mRNA Precursors$325,710
R01 · FY2012 · GM · contact PI
Mechanisms of Eukaryotic Transcriptional Regulation$309,425
R01 · FY2012 · GM · contact PI
Splicing of mRNA Precursors$325,710
R01 · FY2011 · GM · contact PI
Mechanisms of Eukaryotic Transcriptional Regulation$309,425
R01 · FY2011 · GM · contact PI
Splicing of mRNA Precursors$328,750
R01 · FY2010 · GM · contact PI
Mechanisms of Eukaryotic Transcriptional Regulation$312,313
R01 · FY2010 · GM · contact PI
Role of Lipocalin 24p3 in Apoptosis and Leukemia$252,065
R01 · FY2010 · CA · contact PI
Role of Lipocalin 24p3 in Apoptosis and Leukemia$252,065
R01 · FY2009 · CA · contact PI
Mechanisms of Eukaryotic Transcriptional Activation$288,899
R01 · FY2008 · GM · contact PI
Splicing of mRNA Precursors$277,343
R01 · FY2008 · GM · contact PI
Role of Lipocalin 24p3 in Apoptosis and Leukemia$252,065
R01 · FY2008 · CA · contact PI
Mechanisms of Eukaryotic Transcriptional Activation$288,899
R01 · FY2007 · GM · contact PI
Splicing of mRNA Precursors$277,343
R01 · FY2007 · GM · contact PI
Role of Lipocalin 24p3 in Apoptosis and Leukemia$252,065
R01 · FY2007 · CA · contact PI
Mechanisms of Eukaryotic Transcriptional Activation$297,300
R01 · FY2006 · GM · contact PI
Splicing of mRNA Precursors$285,626
R01 · FY2006 · GM · contact PI
Role of Lipocalin 24p3 in Apoptosis and Leukemia$259,395
R01 · FY2006 · CA · contact PI
Mechanisms of Eukaryotic Transcriptional Activation$303,750
R01 · FY2005 · GM
Splicing of mRNA Precursors$291,600
R01 · FY2005 · GM
Intracellular Localization of HIV-1 RNAs by Rev&Matrix$278,250
R01 · FY2005 · AI
Intracellular Localization of HIV-1 RNAs by Rev&Matrix$278,250
R01 · FY2004 · AI
TRANSCRIPTION ACTIVATION BY HIV, TAT, HTLV TAX &HBV PX$269,640
R01 · FY2004 · AI
Splicing of mRNA Precursors$209,880
R01 · FY2004 · GM
Intracellular Localization of HIV-1 RNAs by Rev&Matrix$278,250
R01 · FY2003 · AI
TRANSCRIPTION ACTIVATION BY HIV, TAT, HTLV TAX &HBV PX$269,640
R01 · FY2003 · AI
Splicing of mRNA Precursors$209,880
R01 · FY2003 · GM
MECHANISMS OF EUKARYOTIC TRANSCRITIONAL ACTIVATION$192,200
R01 · FY2003 · GM
Intracellular Localization of HIV-1 RNAs by Rev&Matrix$277,666
R01 · FY2002 · AI
TRANSCRIPTION ACTIVATION BY HIV, TAT, HTLV TAX &HBV PX$229,194
R01 · FY2002 · AI
Splicing of mRNA Precursors$209,880
R01 · FY2002 · GM
MECHANISMS OF EUKARYOTIC TRANSCRITIONAL ACTIVATION$192,200
R01 · FY2002 · GM
TRANSCRIPTION ACTIVATION BY HIV, TAT, HTLV TAX &HBV PX$269,640
R01 · FY2001 · AI
Intracellular Localization of HIV-1 RNAs by Rev&Matrix$260,862
R01 · FY2001 · AI
Splicing of mRNA Precursors$207,240
R01 · FY2001 · GM
MECHANISMS OF EUKARYOTIC TRANSCRITIONAL ACTIVATION$192,200
R01 · FY2001 · GM
HIV-1 REV PROTEIN--BIOCHEMICAL MECHANISMS$277,567
R01 · FY2000 · AI
TRANSCRIPTION ACTIVATION BY HIV, TAT, HTLV TAX &HBV PX$269,640
R01 · FY2000 · AI
MECHANISMS OF EUKARYOTIC TRANSCRITIONAL ACTIVATION$192,200
R01 · FY2000 · GM
SPLICING OF MRNA PRECURSORS$156,205
R01 · FY2000 · GM